Chronic Spontaneous Urticaria: Understanding the Burden, Diagnosis and Treatment Journey: WCM24 CME Satellite Symposium
Chronic Spontaneous Urticaria: Understanding the Burden, Diagnosis and Treatment Journey
This activity is supported by educational grants from Genentech, a member of the Roche Group, Novartis Pharmaceuticals Corporation and Sanofi and Regeneron Pharmaceuticals, Inc.
At the completion of this activity, participants should be better able to:
Describe the burden of CSU and potential impacts to patient quality of life
Discuss strategies for optimizing the diagnosis of CSU
Define the role of targeted therapies for the treatment and management of CSU
Identify approaches for the delivery of optimal patient-centered care in CSU
Aaron Farberg, MD
Baylor Scott & White Health System
Dawn Merritt, DO
Dermatology Residency Program Director
OhioHealth Riverside Hospital
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Speakers’ Bureau or Honoraria: Novartis, Sanofi Regeneron, SUN Pharma, Galderma, Castle Biosciences, Janssen, Ortho Dermatologics, Pfizer
Consultant: Abbvie, Arcutis, BMS, Dermavant, Lilly, Novartis, UCB
Speaker's Bureau or Honoraria: Abbvie, Amgen, BMS, Dermavent, LEO, Lilly, Pfizer
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.